Maze Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Maze Therapeutics, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of up to 9.2 million shares of common stock by existing selling stockholders.
NASDAQ
Maze Therapeutics has filed a registration statement to increase the number of shares offered in its public offering by 1,092,500, including an underwriter option.
NASDAQ
S-1/A: Maze Therapeutics Files for IPO, Aims to Revolutionize Treatment of Kidney and Metabolic Diseases
Maze Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to advance its pipeline of precision medicines for renal, cardiovascular, and metabolic diseases.
NASDAQ
Maze Therapeutics, a clinical-stage biopharmaceutical company, has filed for an initial public offering to fund the development of its precision medicines for renal, cardiovascular, and metabolic diseases.
NASDAQ
Maze Therapeutics, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an initial public offering to fund the development of its precision medicines targeting renal, cardiovascular, and metabolic diseases.